Back to News
Market Impact: 0.12
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals

New analysis of ADAS-Cog data from the company’s randomized, sham-controlled trial reports specific cognitive-domain improvements tied to memory in Alzheimer’s patients, building on earlier publications in the Journal of Alzheimer’s Disease and Radiology. The update is supportive of clinical signals but provides no quantified effect sizes in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- The inside story on the historic U.S.-Venezuela oil deal and how it will work
- Oracle’s AI Cloud Growth Eases Buildout Concerns
- OpenAI has paused its $200 ChatGPT sign-ups as ‘unprecedented’ demand for new model Astra strains its system
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying
- Meet Ottava, J&J's surgical robot leading the healthcare giant into a lucrative new market
- This logistics company’s growth is hiding in its pipeline. Investors have a chance to be early to the upside